How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing
Project Optimus – FDA’s New Dose Optimization & Selection Paradigm in Oncology Drug Development
Oncology Drug Development and Dose Optimization: What Are the Implications of Project Optimus?
Dose optimization in early phase oncology trials, Zheng Liu, IQVIA
Using Modeling and Simulation to Optimize Dosing of an Anti-Infective for Children
Model Informed Drug Development Approaches for Immunogenicity Assessments Workshop
Designs of dose escalation studies in phase I oncology trials
What you should know about FDA Project Optimus for your oncology drug approval
Mechanistic model-informed discovery & development of bispecific antibodies for immuno-oncology
Quantitative and Systems Pharmacology Approaches for the Development of Oncology Drugs
Webinar: Phase I trials in oncology: Pros and cons of current designs
Model-based Designs in Oncology Dose-finding Studies
Bench to Bedside Chat Pharmacology and Dose Optimization for First-in-Human Oncology Trials
Getting the Best Dose: The Clinical Pharmacology Studies that Help Achieve this Goal
Phase 2 Dose-finding Studies with MCP and Modelling Techniques
Practical Model-based Approaches for Phase 1 Oncology Trials
Single and Dual Agent Oncology Dose-Escalation Designs in East® 6.4 - Pantelis Vlachos
